Mergers & Acquisitions
Advanced Enzyme Technologies Lifts JC Biotech Holding to 96.94% With ₹22.80 Million Share Purchase
By News Desk ·
Key takeaways
- Advanced Enzyme Technologies acquired 2,53,297 JC Biotech shares at ₹90 per share for ₹22.80 million.
- The purchase lifted Advanced Enzyme Technologies' stake in JC Biotech from 95.72% to 96.94%.
- Advanced Enzyme Technologies is acquiring the remaining 3.06% of JC Biotech to make it a wholly owned subsidiary.
Advanced Enzyme Technologies acquired an additional 1.22% equity stake in its subsidiary JC Biotech Private Limited for ₹22.80 million, buying 2,53,297 shares at ₹90 each. ScanX reported that the purchase was completed on November 18, 2026, following an initial intimation on August 8, 2026.
Advanced Enzymes' JC Biotech Share Purchase
The transaction involved buying the shares from selling shareholders, and it raised Advanced Enzyme Technologies' holding in JC Biotech from 95.72% to 96.94% of the paid-up share capital. The company said it is in the process of acquiring the remaining 3.06% stake, after which JC Biotech will become a wholly owned subsidiary.
The ₹90 per share price sets a valuation benchmark for the minority interest being consolidated. With the parent now holding nearly 97% of the subsidiary, the remaining 3.06% is a small fraction of the total capital structure.
Earlier Moves on JC Biotech and Capital
On August 8, 2026, Advanced Enzyme Technologies' board approved a share buyback of up to 1,394,000 equity shares at ₹500 per share, aggregating ₹697 million, and the acquisition of the remaining 4.28% stake in JC Biotech for ₹79.79 million, ScanX reported. On November 3, 2026, the company applied to BSE and NSE to reclassify nine promoter group members from 'Promoter Group' to 'Public' under Regulation 31A, with the affected members holding 59,000 shares, or 0.05% of total holding, according to ScanX.
Healthcare Deals Elsewhere in November
The Times of India reported on November 19, 2026, that Blackstone-backed Aster DM Healthcare is in talks to acquire assets from Narayana Hrudayalaya, potentially paying up to $150 million. Dealroom.co reported on November 18, 2026, that Patria Investimentos cleared the final regulatory hurdle for its roughly $1 billion buyout of Chile's Banmédica from UnitedHealth Group.
Remaining Stake and Wholly Owned Status
Advanced Enzyme Technologies has said it is currently acquiring the remaining 3.06% of JC Biotech, after which the subsidiary will be wholly owned. The November 18, 2026 purchase followed the initial intimation on August 8, 2026.
Companies in this story
- Advanced Enzymes · www.advancedenzymes.com
- JC Biotech company profile · jcbiotech.com